Show simple item record

dc.contributor.authorHossain, Jubayer
dc.contributor.authorMarchini, Antonio
dc.contributor.authorFehse, Boris
dc.contributor.authorBjerkvig, Rolf
dc.contributor.authorMiletic, Hrvoje
dc.date.accessioned2021-06-17T12:07:17Z
dc.date.available2021-06-17T12:07:17Z
dc.date.created2021-02-10T13:15:41Z
dc.date.issued2020
dc.identifier.issn2632-2498
dc.identifier.urihttps://hdl.handle.net/11250/2759981
dc.description.abstractSuicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.en_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSuicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospectsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2020en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1093/noajnl/vdaa013
dc.identifier.cristin1888519
dc.source.journalNeuro-Oncology Advances (NOA)en_US
dc.source.402
dc.source.141
dc.source.pagenumber1-12en_US
dc.identifier.citationNeuro-Oncology Advances. 2020, 2 (1), 1-12.en_US
dc.source.volume2en_US
dc.source.issue1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal